risks of glp 1 agonists The promise and peril GLP-1 agonists: What we do (and don't) know as of August 2024 Part 2 of a 3-Part
Description
Manitpisitkul, P
One study author noted, "Understanding the potential side effects of these treatment modalities, though rare, may help individuals and their care teams weigh each treatment's risks and benefits to develop a personalized regimen" [4]
Due to their diverse structures, the pharmacokinetic profiles vary, and a prolonged half-life may be associated with an increased risk of adverse events
Simonsen et al used the Norwegian and Danish national health registries and found an increased risk of NAION development with semaglutide initiation (HR = 2.81)
